Banca de DEFESA: CAIO VINÍCIUS IBIAS BELARDINELLI DE AZEVEDO

Uma banca de DEFESA de MESTRADO foi cadastrada pelo programa.
STUDENT : CAIO VINÍCIUS IBIAS BELARDINELLI DE AZEVEDO
DATE: 07/08/2025
TIME: 14:00
LOCAL: A definir
TITLE:

Development of a non-motor model of Parkinson’s disease and evaluation of antiparkinsonian and toxicology of the nanoencapsulated peptide Fraternine-10.

KEY WORDS:

Non-motor symptoms; Parkinson's disease; 6-OHDA; peptide; toxicity.

PAGES: 100
BIG AREA: Ciências da Saúde
AREA: Medicina
SUMMARY:

“Parkinson’s disease (PD) is one of the most prevalent neurodegenerative diseases in the world, affecting around 10 million people. Mainly characterized by the degeneration of dopaminergic neurons in the substantia nigra, resulting in classic motor symptoms, like bradykinesia, resting tremor, muscle rigidity and gait abnormality. Furthermore, PD also involves non-motor symptoms, including gastrointestinal dysfunction, sleep abnormality, cognitive deficits, depression and anxiety, which impact significantly patients’ quality of life, although often neglected in therapeutic protocols. Fraternine-10, is a peptide with therapeutic potential for PD, nevertheless its effective doses showed limitations due to toxicity, additionally no studies regarding non-motor symptoms. Nanotechnology emerges as a promising strategy to overcome these challenges, since encapsulating the peptide in a nanoparticle could reduce toxicity and improve bioavailability. Taking this into consideration, the object of this work is to evaluate the effects of Fraternine-10 nanoencapsulated (NF-10) in an experimental model of PD which encompass motor and non-motor symptoms, induced by the neurotoxin 6-hidroxidopamine (6-OHDA). The nanoparticle developed displayed stability of its physical-quimical properties throughout the 120 days period. Three doses of NF-10 (20, 10 and 5 µg/animal) and three doses of the peptide in free form were evaluated, utilizing a single dose toxicity protocol, according to ANVISA bylines. Motor and behavioral aspects were analyzed using open field and rotarod. Furthermore, body mass and histological analysis of organs were made, with no alterations observed in any of the groups. For the evaluation of the non-motor symptoms, two doses of 6-OHDA (40 e 30 µg/animal) were tested, 30 µg/animal dose was chosen due to showing significant anxiety-like behavior in the elevated plus maze test (EPM). In the therapeutic stage, the animals were submitted to LCE (anxiety), to open field test (motor and behavior parameters) and new object recognition test (NORT) to analyze long memory. Three experimental groups were formed: vehicle, 6-OHDA (30 µg/animal) and NF-10 (10 µg/animal). The group treated with NF-10 showed significant improvement in anxious behavior compared to 6-OHDA group in EPM. However, no motor improvement was seen in the open field test. In the NORT test, the 6-OHDA group displayed memory deficit compared to the vehicle group, and treatment with NF-10 was unable to revert the loss. The results suggests that the nanoformulation of NF-10 was safe, no toxicity was presented in any dose, and it promotes a anxiolytic effect in the experimental model of PD, however it was unable to impact cognitive deficits induce by 6-OHDA.

COMMITTEE MEMBERS:
Externo à Instituição - CLEITON LOPES AGUIAR - UFMG
Presidente - 2567703 - MARCIA RENATA MORTARI
Externo ao Programa - 1744566 - MAURICIO HOMEM DE MELLO - nullInterno - 1952915 - RAFAEL PLAKOUDI SOUTO MAIOR